FORUS Therapeutics is pleased to announce that XPOVIO® (selinexor) is now publicly funded in Ontario, Newfoundland and Labrador, and New Brunswick. Please see the following links for full funding criteria:
- Ontario: Exceptional Access Program | ontario.ca
- Newfoundland and Labrador: Special Authorization Drug Products – Health and Community Services (gov.nl.ca)
- New Brunswick: NB-Drug-Plans-Bulletin-1115.pdf (gnb.ca)
We are excited about these important milestones for patients in Canada.
Read on LinkedIn